Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the addition of a unique targeted agent called
Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard
treatment with chemotherapy and radiation.